2026-05-17T01:16:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/113442024-11-29T23:20:21Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Cedena, Maria-Teresa author Martin-Clavero, Estela author Wong, Sandy author Shah, Nina author Bahri, Natasha author Alonso, Rafael author Barcenas, Carmen author Valeri, Antonio author Salazar Tabares, Johny author Sanchez-Pina, Jose author Cuellar, Clara author Martin, Thomas author Wolf, Jeffrey author Lahuerta, Juan José author Martinez-Lopez, Joaquin author 2020-08-31 Stringent complete response (sCR) is used as a deeper response category than complete response (CR) in multiple myeloma (MM) but may be of limited value in the era of minimal residual disease (MRD) testing. Here, we used 4-colour multiparametric flow cytometry (MFC) or next-generation sequencing (NGS) of immunoglobulin genes to analyse and compare the prognostic impact of sCR and MRD monitoring. We included 193 treated patients in two institutions achieving CR, for which both bone marrow aspirates and biopsies were available. We found that neither the serum free light chain ratio, clonality by immunohistochemistry (IHC) nor plasma cell bone marrow infiltration identified CR patients at distinct risk. Patients with sCR had slightly longer progression-free survival. Nevertheless, persistent clonal bone marrow disease was detectable using MFC or NGS and was associated with significantly inferior outcomes compared with MRD-negative cases. Our results confirm that sCR does not predict a different outcome and indicate that more sensitive techniques are able to identify patients with differing prognoses. We suggest that MRD categories should be implemented over sCR for the future classification of MM responses. PLoS One 2020 ;15(8):e0237155. 10.1371/journal.pone.0237155 PloS one 32866200 http://hdl.handle.net/20.500.12105/11344 STEM-CELL TRANSPLANTATION DEEP-SEQUENCING METHOD CRITERIA THERAPY IMPACT The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.